• 1
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001; 51: 1536.
  • 2
    Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest. 1994; 106: 861865.
  • 3
    Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol. 1988; 6: 633641.
  • 4
    Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000; 18: 122130.
  • 5
    Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus navelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998; 16: 24592465.
  • 6
    Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000; 18: 623631.
  • 7
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 9298.
  • 8
    Bhargava P, Marshall JL, Fried K, et al. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients administered weekly to patients with advanced cancer. Cancer Chemother Pharmacol. 2001; 48: 95103.
  • 9
    Andersson BS, Luna MA, Yee C, et al. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia. Cancer. 1990; 65: 10791084.
  • 10
    Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997; 80: 286291.
  • 11
    Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol. 1998; 15: 34263432.
  • 12
    Etienne B, Perol M, Nesme P, et al. Acute diffuse interstitial pneumopathy following docetaxel (Taxotere). Apropos of 2 cases. Rev Mal Respir. 1998; 15: 199203.
  • 13
    Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer. 2002; 94: 847853.
  • 14
    Rebattu P, Quantin X, Ardiet C, et al. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Lung Cancer. 2001; 33: 277287.
  • 15
    Dunsford ML, Mead GM, Bateman AC, et al. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol. 1999; 10: 943947.
  • 16
    Thomas AL, Cox G, Sharma RA, et al. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer. 2000; 36: 23292334.
  • 17
    Georgoulias V, Kouroussis C, Androulakis N, et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol. 1999; 17: 914920.
  • 18
    Ventriglia M, Estevez R, Alume H, et al. Docetaxel (Taxotere) plus gemcitabine (Gemtro). A new combination in the treatment of patients with advanced non-small cell lung cancer. A preliminary analysis [abstract 365]. Ann Oncol. 1998; 9: 96.
  • 19
    Rubio G, Blajman C, Capó, A, et al. Docetaxel and gemcitabine in metastatic non-small-cell lung cancer (NSCLC). A phase II study. Preliminary feasibility report. Proc Am Soc Clin Oncol. 1999; 19: 2012a.
  • 20
    Hejna M, Kornek GV, Raderer M, et al. Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor. Cancer. 2000; 89: 516522.
  • 21
    Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 2001; 357: 14781484.
  • 22
    Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991; 9: 16181626.
  • 23
    Jiroutek M, Johnson D, Blum R, et al. Prognostic factors in advanced non-small cell lung cancer (NSCLC): analysis of Eastern Cooperative Oncology Group trials from 1981-1992 [abstract]. Proc Am Soc Clin Oncol. 1998; 17: 461.